Abstract
Background
Intractable serous (not chylous) ascites (IA) that infrequently develops early following pancreaticoduodenectomy (PD) for pancreatic cancer is a life-threatening problem. The relationship between neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer and the incidence of IA following PD has not been evaluated. This study aims to identify the risk factors associated with IA that develops early after PD for pancreatic cancer.
Methods
We retrospectively identified 94 patients who underwent PD for pancreatic cancer at the Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Osaka, Japan, from April 2012 to March 2020. Data on 29 parameters were obtained from medical records. Univariate and multivariate analyses were conducted to identify independent risk factors. Levels of serum albumin were compared before and after NACRT to analyze its effect. Survival analysis was also conducted.
Results
Of the 92 patients included in this study, 8 (8.70%) were categorized into the IA group. Multivariate analysis identified NACRT [odds ratio (OR) 27, 95% confidence interval (CI) 1.87–394, p = 0.016)] and hypoalbuminemia (≤ 1.6 g/dl) just after the operation (OR 50, 95% CI 1.68–1516, p = 0.024) as risk factors. The level of serum albumin was significantly decreased following NACRT. The IA group had poorer prognosis than the control group.
Conclusions
IA is a serious problem that aggravates patient’s prognosis. Postoperative lymphatic leak might be a trigger of IA. NACRT was a major risk factor, followed by hypoalbuminemia caused by various reasons. These factors may act synergistically and cause IA.
Similar content being viewed by others
References
Weniger M, D’Haese JG, Angele MK, et al. Treatment options for chylous ascites after major abdominal surgery: a systematic review. Am J Surg. 2016;211:206–13.
Kuboki S, Shimizu H, Yoshidome H, et al. Chylous ascites after hepatopancreatobiliary surgery. Br J Surg. 2013;100:522–7.
Assumpcao L, Cameron JL, Wolfgang CL, et al. Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg. 2008;12:1915–23.
Singh H, Pandit N, Krishnamurthy G, et al. Management of chylous ascites following pancreaticobiliary surgery. JGH Open. 2019;3:425–8.
Pabst TS, McIntyre KE, Schilling JD, et al. Management of chyloperitoneum after abdominal aortic surgery. Am J Surg. 1993;166:194–8.
Tabchouri N, Frampas E, Marques F, et al. Chylous ascites management after pancreatic surgery. World J Surg. 2017;41:1054–60.
7. Van der Gaag NA, Verhaar AC, Haverkort EB, et al. Chylous ascites after pancreaticoduodenectomy: introduction of a grading system. J Am Coll Surg. 2008;207:751–7.
Kaas R, Rustman LD, Zoetmulder FA. Chylous ascites after oncological abdominal surgery: incidence and treatment. Eur J Surg Oncol. 2001;27:187–9.
Strobel O, Brangs S, Hinz U, et al. Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery. Br J Surg. 2017;104:108–17.
Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 2016;39:302–13.
Versteijne E, van Eijck CH, Punt CJ, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17:127.
Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(6):vi1–vi12.
Kostov S, Yordanov A, Slavchev S, et al. First case of chylous ascites after laparoscopic myomectomy: A case report with a literature review. Medicina (Kaunas). 2019;55:624. https://doi.org/10.3390/medicina55100624.
Ahmed S, Shaw G, Al Kadhi O. Massive ascites following robot-assisted radical prostatectomy and extended pelvic lymph node dissection: a case report. J Endourol Case Rep. 2019;5:139–41.
Pan W, Yang C, Cai S-Y et al. Incidence and risk factors of chylous ascites after pancreatic resection. Int J Clin Exp Med. 2015;8:4494–500.
16. Kojima M, Inoue M, Yamamoto S, et al. Successful treatment of hepatic lymphorrhea by percutaneous transhepatic lymphangiography followed by sclerotherapy using OK-432. Surg Case Rep. 2019;5:1–6.
Tanaka K, Ohmori Y, Mohri Y, et al. Successful treatment of refractory hepatic lymphorrhea after gastrectomy for early gastric cancer, using surgical ligation and subsequent OK-432 (picibanil) sclerotherapy. Gastric Cancer. 2004;7:117–21.
Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: a collective review. Surgery. 2000;128:761–78.
Kwon S, Janssen CF, Velasquez FC, et al. Radiation dose-dependent changes in lymphatic remodeling. Int J Radiat Oncol Biol Phys. 2019;105:852–60.
Baselet B, Sonveaux P, Baatout S, et al. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728.
Jørgensen MG, Toyserkani NM, Hansen CR, et al. Quantification of chronic lymphedema in a revised mouse model. Ann Plast Surg. 2018;81:594–603.
Haubner F, Ohmann E, Pohl F, Strutz J, et al. Wound healing after radiation therapy: review of the literature. Radiat Oncol. 2012;7:162. https://doi.org/10.1186/1748-717X-7-162.
Sawada K, Fujioka-Kobayashi M, Kobayashi E, et al. In vitro effects of 0 to 120 grays of irradiation on bone viability and release of growth factors. BMC Oral Health. 2016;17:4. https://doi.org/10.1186/s12903-016-0241-9.
Sim EH, Kwon JH, Kim SY, et al. Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy. Clin Mol Hepatol. 2012;18:404–10.
Song SC, Choi SH, Choi DW, et al. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol. 2011;17(32):3716–23.
Kang CM, Lee JH. Pathophysiology after pancreaticoduodenectomy. World J Gastroenterol. 2015;21:5794–804.
Wittmann D, Hall WA, Christians KK, et al. Impact of neoadjuvant chemoradiation on pathologic response in patients with localized pancreatic cancer. Front Oncol. 2020;10:460. https://doi.org/10.3389/fonc.2020.00460.
Acknowledgments
The authors would like to thank Enago (www.enago.jp) for the English language review.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There is no commercial interest in this study.
Ethical Aproval
The study was approved by the institutional review boards of Osaka Medical College Hospital (Approval No. 2677, 5 March 2019).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tomioka, A., Shimizu, T., Kagota, S. et al. Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer. Ann Surg Oncol 28, 3789–3797 (2021). https://doi.org/10.1245/s10434-020-09401-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09401-w